Clinical and Scientific Challenges to Effectiveness Studies Under Coverage with Evidence Development in Alzheimer’s Disease

The Centers for Medicare and Medicaid Services (CMS) has recently issued a national coverage determination for US Food and Drug Administration (FDA)-approved anti-amyloid monoclonal antibodies (mAbs) for the treatment of Alzheimer’s disease (AD) under coverage with evidence development (CED). CED sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Morin, Peter J., Zhang, Quanwu, Xia, Weiming, Miller, Donald, Querfurth, Henry, Tahami Monfared, Amir Abbas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195925/
https://www.ncbi.nlm.nih.gov/pubmed/36933140
http://dx.doi.org/10.1007/s40120-023-00462-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195925/
https://www.ncbi.nlm.nih.gov/pubmed/36933140
http://dx.doi.org/10.1007/s40120-023-00462-z

Ejemplares similares